{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2021_00017672", "CSN": null, "TRF": "ORD_1247965_01", "MRN": "38827315", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "943747", "clinicalId": "945131", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1247965_01", "SampleName": "US1204172.01", "Version": "0", "Sample": {"FM_Id": "ORD_1247965_01", "SampleId": "US1204172.01", "BlockId": "S110-34918B", "TRFNumber": "ORD_1247965_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2021_11_29", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "50", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S110-94793", "MRN": "38827315", "FullName": "\u7d00\u76c8\u5b8f", "FirstName": "Ying_Hung", "LastName": "Chi", "SubmittedDiagnosis": "Anaplastic astrocytoma, Cerebrum", "Gender": "Male", "DOB": "1987_01_25", "OrderingMD": "\u8a31\u79c9\u6b0a", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Brain", "CollDate": "2021_11_15", "ReceivedDate": "2021-12-14 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Diffuse Glioma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "14", "clinicalTrialCount": "10", "resistiveCount": "0", "sensitizingCount": "1"}, "VariantProperties": {"VariantProperty": [{"geneName": "FANCA", "isVUS": "true", "variantName": "R591Q"}, {"geneName": "IDH2", "isVUS": "true", "variantName": "R188Q"}, {"geneName": "KMT2A (MLL)", "isVUS": "true", "variantName": "A53V"}, {"geneName": "MAP3K1", "isVUS": "true", "variantName": "R1023H"}, {"geneName": "PDCD1 (PD_1)", "isVUS": "true", "variantName": "A80V"}, {"geneName": "SMARCA4", "isVUS": "true", "variantName": "K546del"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "IDH1", "Include": "true", "Alterations": {"Alteration": {"Name": "R132G", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R132G"}}, "Interpretation": "The isocitrate dehydrogenases IDH1 and IDH2 encode highly homologous enzymes that are involved in the citric acid (TCA) cycle and other metabolic processes, playing roles in normal cellular metabolism and in protection against oxidative stress and apoptosis (Reitman and Yan, 2010; 20513808). R132 is located within the active site of IDH1 and is a hotspot for mutations in cancer (Jin et al., 2011; 21326614, Gross et al., 2010; 20142433, Ward et al., 2010; 20171147, Leonardi et al., 2012; 22442146, Reitman and Yan, 2010; 20513808). Substitutions at IDH1 R132 alter the enzymatic activity of IDH1, resulting in the production of the oncometabolite, D_2_hydroxyglutarate (2_HG)(Dang et al., 2009; 19935646, Ward et al., 2012; 21996744, Ward et al., 2010; 20171147, Gross et al., 2010; 20142433, Leonardi et al., 2012; 22442146), which promotes tumorigenesis (Gross et al., 2010; 20142433, Figueroa et al., 2010; 21130701, Xu et al., 2011; 21251613, Turcan et al., 2012; 22343889, Duncan et al., 2012; 22899282). IDH1 mutation is characteristic of low_grade gliomas and secondary glioblastoma, and is relatively rare in primary glioblastoma (Chaumeil et al., 2013; 24019001, Hartmann et al., 2013; 23918605, Rossetto et al., 2011; 21885076, Shin et al., 2013; 24129546, Parsons et al., 2008; 18772396). In the TCGA datasets, IDH1 mutation has been found in 77% of lower grade glioma cases and in 5% of glioblastoma cases (Cancer Genome Atlas Research Network., 2015; 26061751, cBio_Brennan et al., 2013; 24120142). IDH1 mutations are highly prevalent in grade 2 and grade 3 astrocytoma, oligodendroglioma, and oligoastrocytoma, reported in 43_100% of grade 2 tumors and 45_93% of grade 3 tumors (Thota et al., 2012; 22904127, Killela et al., 2013; 24140581, Haberler and W\u00f6hrer, 2014; 24559763, Yan et al., 2009; 19228619). IDH1/2 mutations are a strong favorable prognostic marker for OS in Grade 2_3 glioma, particularly in combination with 1p/19q codeletion (NCCN CNS Cancers Guidelines, v5.2020). Several studies have found IDH1 mutations to be associated with improved prognosis and longer PFS and OS in patients with various types of glioma including anaplastic astrocytoma and GBM (Hartmann et al., 2010; 21088844, Sonoda et al., 2009; 19765000, Ahmadi et al., 2012; 22528790, Jiang et al., 2013; 23486687, Shibahara et al., 2012; 21971842, Parsons et al., 2008; 18772396, Juratli et al., 2012; 23015095, Weller et al., 2009; 19805672). IDH1 mutations that lead to production of 2_HG, most commonly R132 alterations, may predict sensitivity to IDH1_mutation_specific inhibitors such as ivosidenib (Abou_Alfa et al., 2019; ESMO Abstract LBA10, Fan et al., 2019; 31028664, Mellinghoff et al., 2017; SNO Abstract ACTR_46, Tap et al., 2016; CTOS Abstract P1_138). A Phase 1b/2 study of the IDH1 inhibitor olutasidenib for patients with IDH1_mutated glioma reported a DCR of 50% (n=24) with 1 PR (De La Fuente et al., 2020; ASCO Abstract 2505). A Phase 1 study of the pan_IDH1/IDH2 inhibitor vorasidenib for patients with IDH1_ or IDH2_mutated glioma reported an ORR of 18.2% (4/22; RANO criteria) and median PFS of 31.4 months for non_enhancing cases and median PFS of 7.5 months for the overall glioma population (n=52) (Mellinghoff et al., 2020; ASCO Abstract 2504). Preclinical studies suggested that IDH1 neomorphic mutations may also confer sensitivity to PARP inhibitors (Philip et al., 2018; 29719265, Molenaar et al., 2018; 29339439, Lu et al., 2017; 28202508, Sulkowski et al., 2017; 28148839). In a Phase 1 trial of the PD_L1 inhibitor atezolizumab in patients with glioblastoma (GBM), 2 of the 3 patients with IDH1_mutant tumors experienced clinical benefit (1 PR and 1 long_term SD; the third patient experienced short_term SD), whereas none of the 8 patients with IDH1_wild_type GBM experienced benefit (8/8 PD); significantly longer PFS and a trend toward longer OS were observed in the patients with IDH1_mutated tumors compared to the patients with IDH1_wild_type tumors (Lukas et al., 2018; 30073642). Preclinical data indicate that IDH1_mutated glioma may be sensitive to the glutaminase inhibitor telaglenastat in combination with radiotherapy (McBrayer et al., 2018; 30220459, Kizilbash et al., 2019; ASCO Abstract TPS2075). IDH1/2 mutations are associated with improved survival outcomes for patients treated with radiation or alkylating chemotherapy (NCCN CNS Cancers Guidelines, v5.2020). IDH1/2 mutation is associated with Grade 2 and 3 astrocytomas and oligodendrogliomas, and distinguishes secondary glioblastoma (GBM) from primary GBM (NCCN CNS Cancers Guidelines, v5.2020).", "Include": "true", "ClinicalTrialNote": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Therapies": {"Therapy": {"Name": null, "GenericName": "Ivosidenib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Ivosidenib is an isocitrate dehydrogenase 1 (IDH1) inhibitor that is FDA approved to treat patients with a susceptible IDH1 mutation in relapsed or refractory acute myeloid leukemia (AML) or previously treated locally advanced or metastatic cholangiocarcinoma. It is also approved as a first_line treatment for patients with AML and a susceptible IDH1 mutation who are not eligible for intensive induction chemotherapy or who are \u226575 years old. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of extensive clinical evidence in AML (DiNardo et al., 2018; 29860938) and cholangiocarcinoma (Lowery et al., 2019; 31300360, Abou_Alfa et al., 2020; 32416072) and limited clinical data in myelodysplastic syndrome (MDS) (DiNardo et al., 2018; 29860938) and glioma (Mellinghoff et al., 2020; 32530764, Fan et al., 2019; 31028664), IDH1 R132 mutation may confer sensitivity to ivosidenib. </p> <p><b>Supporting Data:</b> In a Phase 1 study of ivosidenib for patients with IDH1_mutated advanced solid tumors, 1 patient achieved PR in the non_enhancing glioma population (ORR=2.9% [1/35]); for patients with non_enhancing glioma and enhancing glioma, SD rates were 85.7% (30/35) and 45.2% (14/31), respectively, and median PFS was 13.6 months and 1.4 months, respectively (Mellinghoff et al., 2020; 32530764, Fan et al., 2019; 31028664). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04740190", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04497116", "Include": "true"}, {"nctId": "NCT03907969", "Include": "true"}, {"nctId": "NCT03830918", "Include": "true"}, {"nctId": "NCT03914742", "Include": "true"}, {"nctId": "NCT03212274", "Include": "true"}, {"nctId": "NCT03221400", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "ATRX", "Include": "true", "Alterations": {"Alteration": {"Name": "E886fs*18", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E886fs*18"}}, "Interpretation": "ATRX encodes a SWI/SNF chromatin remodeling protein implicated in histone variant H3.3 deposition, transcriptional regulation, and telomere maintenance (Clynes et al., 2013; 23916100, Ratnakumar and Bernstein, 2013; 23249563). ATRX inactivation or loss of expression is associated with alternative lengthening of telomeres (ALT)(Lovejoy et al., 2012; 22829774, Bower et al, 2012; 23185534; Heaphy et al., 2011; 21719641, Liau et al., 2015; 25229770). Alterations that disrupt the ADD domain (aa 167_270) or helicase domain (aa 2010_2280) of ATRX are predicted to result in loss of ATRX function (Nan et al., 2007; 17296936, Garrick et al., 2004; 14729260, Eustermann et al., 2011; 21666677); however, the loss of ATRX function is not sufficient to induce ALT, which requires other undetermined factors (Clynes et al., 2013; 23916100, Flynn et al., 2015; 25593184). Germline mutations in ATRX give rise to alpha_thalassemia X_linked intellectual disability syndrome (ATR_X syndrome)(Gibbons et al., 1995; 7697714). Somatic mutation of ATRX has been reported in a number of solid tumor types, often associated with ALT (Heaphy et al., 2011; 21719641). ATRX mutation correlating with ALT has been reported in 10_20% of pancreatic neuroendocrine tumors (PNETs)(Singhi et al., 2015; USCAP Abstract 1797)(Jiao et al., 2011; 21252315, Heaphy et al., 2011; 21719641), 12.6% of pheochromocytomas and paragangliomas (Fishbein et al., 2015; 25608029), and 48% of adolescent and young adult (AYA) patients with glioblastoma (GBM) or neuroblastoma (Morosini et al., 2014; ASCO Abstract 11008)(Cheung et al., 2012; 22416102, Molenaar et al., 2012; 22367537, Pugh et al., 2013; 23334666, Cheung and Dyer, 2013; 23702928). ATRX loss in PNET (Singhi et al., 2015; USCAP Abstract 1797)(Marinoni et al., 2014; 24148618) and melanoma (Qadeer et al., 2014; 24468746) and mutation in other neuroendocrine tumors (Fishbein et al., 2015; 25608029) is associated with poor prognosis. Pediatric patients with high_grade glioma and ATRX mutation were shown to have more aggressive disease but are more responsive to treatment with double_strand break therapy (Koschmann et al., 2016; 26936505). ATRX mutation or loss of expression is more frequent in Grade 2/3 astrocytoma and secondary GBM than primary GBM, oligodendroglioma, and oligoastrocytoma (Kannan et al., 2012; 23104868, Haberler and W\u00f6hrer, 2014; 24559763, Reuss et al., 2014; 25427834, Sahm et al., 2014; 25143301) and has been proposed as a distinguishing biomarker (Haberler and W\u00f6hrer, 2014; 24559763, Reuss et al., 2014; 25427834, Sahm et al., 2014; 25143301). ATRX mutation has not been detected in concurrence with MYCN amplification in glioma and neuroblastoma (Cheung et al., 2012; 22416102, Molenaar et al., 2012; 22367537, Pugh et al., 2013; 23334666, Cheung and Dyer, 2013; 23702928). Low_grade gliomas with both IDH1/2 mutation and ATRX mutation are associated with worse prognosis than those with IDH1/2 mutation but no ATRX mutation (Haberler and W\u00f6hrer, 2014; 24559763). Loss of ATRX protein expression has been reported in 33_39% of incidences of leiomyosarcoma (LMS) associating with ALT, a poor prognostic factor across all LMS subtypes, and with poor prognosis in extrauterine LMS but not in uterine LMS (Singhi et al., 2015; USCAP Abstract 93)(Liau et al., 2015; 25229770). No targeted therapies are available to directly address ATRX inactivation. Based on preclinical (Liang et al., 2020; 31551363, Garbarino et al., 2021; 34118569) and limited clinical data (Cole et al., 2021; AACR Abstract CT059), ATRX alterations may confer sensitivity to combination strategies involving WEE1 inhibition. In a Phase 2 study evaluating the WEE1 inhibitor adavosertib plus irinotecan for the treatment of pediatric patients with neuroblastoma, prolonged SD was reported for 44% (4/9) of patients with ATRX_deficient tumors and responses were seen in two tumors that had evidence of ALT (Cole et al., 2021; AACR Abstract CT059). Preclinical evidence also suggests that ATRX deficiency may impart sensitivity to synthetic lethal approaches involving PARP inhibition and irinotecan (George et al., 2020; 32846370), combined PARP and ATR inhibition (Garbarino et al., 2021; 34118569), or double_strand break_induction with agents such as doxorubicin, irinotecan, and topotecan (Koschmann et al., 2016; 26936505); however, these approaches have not been demonstrated clinically. ATRX mutations often co_occur with IDH1/2 mutations and may be indicative of Grade 2_3 astrocytoma or secondary glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v5.2020)(Louis et al., 2016; 27157931).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CDKN2A/B", "Include": "true", "Alterations": {"Alteration": [{"Name": "CDKN2B loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2B loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas (cBio_Ceccarelli et al., 2016; 26824661) and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)(cBio_Brennan et al., 2013; 24120142) than in those with lower grade gliomas (13%) (cBioPortal, Sep 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM) (Verhaak et al., 2010; 20129251, Sottoriva et al., 2013; 23412337, Weber et al., 2007; 16909113). Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples (Chakravarti et al., 2001; 11489817). Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in GBM and likely serves as an early event in GBM progression (Feng et al., 2012; 21713760, Sottoriva et al., 2013; 23412337). In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared to patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter overall survival in pilocytic astrocytomas (Raabe et al., 2011; 21636552, Liu et al., 2011; 21843312). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Although case studies have reported that patients with breast cancer or uterine leiomyosarcoma harboring CDKN2A loss responded to palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889), multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. There are no drugs that directly target the mutation or loss of CDKN2B in cancer. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500)(Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}, {"Name": "CDKN2A loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2A loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas (cBio_Ceccarelli et al., 2016; 26824661) and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)(cBio_Brennan et al., 2013; 24120142) than in those with lower grade gliomas (13%) (cBioPortal, Sep 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM) (Verhaak et al., 2010; 20129251, Sottoriva et al., 2013; 23412337, Weber et al., 2007; 16909113). Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples (Chakravarti et al., 2001; 11489817). Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in GBM and likely serves as an early event in GBM progression (Feng et al., 2012; 21713760, Sottoriva et al., 2013; 23412337). In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared to patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter overall survival in pilocytic astrocytomas (Raabe et al., 2011; 21636552, Liu et al., 2011; 21843312). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Although case studies have reported that patients with breast cancer or uterine leiomyosarcoma harboring CDKN2A loss responded to palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889), multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. There are no drugs that directly target the mutation or loss of CDKN2B in cancer. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500)(Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}]}, "ReferenceLinks": null}, {"Name": "MTAP", "Include": "true", "Alterations": {"Alteration": {"Name": "loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "loss"}}, "Interpretation": "MTAP encodes S_methyl_5 _thioadenosine (MTA) phosphorylase, a tumor suppressor involved in polyamine metabolism and methionine synthesis, although its enzymatic function is dispensable for its tumor suppressor activity (Limm et al., 2016; 27479139, Tang et al., 2014; 25387827). Decreased expression of MTAP leads to MTA accumulation within tumor cells and their microenvironment (Kirovski et al., 2011; 21356366, Limm et al., 2013; 23265702, Stevens et al., 2009; 19097084), thereby reducing intracellular arginine methylation (Marjon et al., 2016; 27068473, Mavrakis et al., 2016; 26912361, Kryukov et al., 2016; 26912360) and altering cell signaling (Limm et al., 2014; 25087184, Stevens et al., 2009; 19097084). MTAP is located at 9p21, adjacent to CDKN2A and CDKN2B, with which it is frequently co_deleted in various cancers. Other alterations in MTAP are rare and have not been extensively characterized. MTAP loss/homozygous deletion as well as loss of expression has been reported in a wide variety of solid tumors and hematologic cancers (Wei et al., 2016; 27929028, Zhao and Zhao, 2016; 27556634); such events have been correlated with poor prognosis in a variety of cancer types, including hepatocellular carcinoma (Kirovski et al., 2011; 21356366), gastrointestinal stromal tumors (Huang et al., 2009; 19887491), mantle cell lymphoma (MCL)(Marce et al., 2006; 16778103), melanoma (Meyer et al., 2010; 20500769, Wild et al., 2006; 16618867), gastric cancer (Kim et al., 2011; 21412930), myxofibrosarcoma (Li et al., 2014; 25426549), nasopharyngeal carcinoma (He et al., 2015; 26656376), ovarian carcinoma (Wei et al., 2016; 27929028) and non_small cell lung cancer (Su et al., 2014; 24969958). MTAP loss was not prognostic in pediatric B_cell acute lymphocytic leukemia (Mirebeau et al., 2006; 16818274) or in astrocytoma (Becker et al., 2015; 26088413). However, MTAP has also been reported to be overexpressed in colorectal cancer (CRC) samples (Snezhkina et al., 2016; 27433286), and MTAP retention is thought to be important for prostate cancer growth due to continuous supply of SAM (Bistulfi et al., 2016; 26910893). Germline SNPs in MTAP have been correlated with the development of cutaneous melanoma (Antonopoulou et al., 2015; 25407435, Mccioni et al., 2013; 23816148), esophageal cancer (Hyland et al., 2016; 26635288, Lin et al., 2017; 27960044), osteosarcoma (Zhi et al., 2016; 27994653), and CRC (Gu et al., 2013; 23361049). Preclinical and limited clinical evidence indicate that MTAP inactivation produces specific metabolic vulnerabilities. MTAP inactivation may confer sensitivity to MAT2A inhibitors (Heist et al., 2019; AACR_NCI_EORTC Abstract B116, Marjon et al., 2016; 27068473). A Phase 1 trial of MAT2A inhibitor AG_270 reported 1 PR and 2 SDs lasting longer than 6 months for patients with advanced solid tumors displaying MTAP loss (Heist et al., 2019; AACR_NCI_EORTC Abstract B116). Although preclinical data have suggested that MTAP loss sensitizes cells to PRMT5 inhibition (Marjon et al., 2016; 27068473, Mavrakis et al., 2016; 26912361, Kryukov et al., 2016; 2691236), MTAP loss may not be a biomarker of response to previously developed small_molecule SAM_uncompetitive PRMT5 inhibitors (Guccione and Richard, 2019; 31350521); dual PRMT1 and PRMT5 inhibition may be more effective (Fedoriw et al., 2019; 31257072, Srour et al., 2019; 31287990, Gao et al., 2019; 30916320). In preclinical cancer models, MTAP inactivation showed increased sensitivity to inhibitors of purine synthesis or purine analogs, especially upon addition of exogenous MTA, which is converted to adenine in normal cells, thereby providing competition to purine poisons lacking in MTAP_deficient cells (Hansen et al., 2019; 31040154, Tang et al., 2018; 29844120, Munshi et al., 2014; 24928612, de Oliveira et al., 2016; 26751376, Lubin and Lubin, 2009; 19478948, Tang et al., 2012; 22825330, Collins et al., 2012; 22252602, Bertino et al., 2011; 21301207, Coulthard et al., 2011; 21282358, Miyazaki et al., 2007; 17912432, Efferth et al., 2002; 11987241). A Phase 2 study of L_alanosine, an inhibitor of adenine synthesis, as a monotherapy for 65 patients with MTAP_deficient cancers reported no responses and stable disease in 23.6% (13/55) of patients (Kindler et al., 2009; 18618081).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_High has been reported in 3_8% of adult or pediatric astrocytomas and was generally not associated with Lynch syndrome (Alonso et al., 2001; 11280776, Rodr\u00edguez_Hern\u00e1ndez et al., 2013; 24073290, Vladimirova et al., 2008; 18053027). Low_level MSI has been reported in 5_9% of glioblastoma (GBM) samples (Martinez et al., 2004; 15331927, Martinez et al., 2005; 15672285, Martinez et al., 2007; 17498554). A large_scale study did not find high_level microsatellite instability (MSI_H) in any of 129 GBM samples (Martinez et al., 2004; 15331927), although a small_scale study reported MSI_H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs (Szybka et al., 2003; 12908754). The frequency of MSI has been reported to be increased in relapsed compared to primary GBM (Martinez et al., 2004; 15331927), in GBMs with a previous lower grade astrocytoma (Martinez et al., 2005; 15672285), and in giant cell GBM compared to classic GBM (Martinez et al., 2007; 17498554). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "R273C", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R273C"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutations have been reported in 18_40% of astrocytoma samples, and preferentially in anaplastic astrocytoma; one study reported TP53 loss of function and partially/fully functional mutations in 15% and 25% of anaplastic astrocytomas, respectively (Uno et al., 2005; 15914282, Uno et al., 2006; 16711514, Lass et al., 2012; 22844452, Faria et al., 2012; 23009112, Milinkovic et al., 2013; 24358143, Galatro et al., 2013; 23613880). Some studies suggest that the presence of a TP53 mutation is correlated with a favorable prognosis in patients with glioblastoma (GBM) (Schmidt et al., 2002; 11939587). One study reported that TP53 alterations were associated with poorer OS (12.9 months altered vs. 19.7 months wildtype, HR=1.58, p=0.0054) in IDH_wildtype GBM (Yan et al. 2020; DOI:10.1200/PO.19.00385). Mutation of TP53 is thought to be an early step in the tumorigenesis of astrocytomas, which can progress into anaplastic astrocytoma and then glioblastoma through gain of other genetic abnormalities such as loss of CDKN2A or RB1, followed by loss of PTEN (Nozaki et al., 1999; 11550308). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% (17/176) and SDs in 53.4% (94/176) of patients with solid tumors; the response rate was 21.1% (4/19) for patients with TP53 mutations versus 12.1% (4/33) for patients who were TP53 wild_type (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 31.9% (30/94, 3 CR) ORR and a 73.4% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 42.9% (9/21, 1 CR) ORR and a 76.2% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24.0% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71.4% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75.0% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53_mutated, but not TP53_wild_type, breast cancer xenotransplant mouse model (Ma et al., 2012; 22446188). Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR_246 (Gourley et al., 2016; ASCO Abstract 5571, Lehmann et al., 2012; 22965953, Mohell et al., 2015; 26086967, Franssonet al., 2016; 27179933). In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, APR_246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Sep 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "03", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "03"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Touat et al., 2020; 32322066, Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556, Lukas et al., 2018; 30073642). Anaplastic astrocytoma harbors a median TMB of 1.8 mutations per megabase (muts/Mb), and 2% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). For pediatric patients, high TMB has been reported in a subset of high_grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB (Patel et al., 2020; 32386112, Johnson et al., 2017; 28912153). Increased TMB has been reported to correlate with higher tumor grade in glioma (Draaisma et al., 2015; 26699864) and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD) (Bouffet et al., 2016; 27001570), as well as with shorter OS of patients with diffuse glioma (Wang et al., 2020; 32164609). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported (Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Touat et al., 2020; 32322066). However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti_PD_1 (Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556) or anti_PD_L1 (Lukas et al., 2018; 30073642) therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD_1 or PD_L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "IDH1", "Alteration": "R132G", "Title": "Talazoparib _ Carboplatin for Recurrent High_grade Glioma With DDRd", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Hong Kong (Hong Kong)", "NCTID": "NCT04740190", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132G", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California", "NCTID": "NCT02264678", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132G", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132G", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132G", "Title": "Study of RP_3500 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP", "Locations": "Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee, Texas", "NCTID": "NCT04497116", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132G", "Title": "A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti_cancer Agents in Patients With Advanced Cancers", "StudyPhase": "PHASE 1/2", "Target": "PARP, DNA_PK", "Locations": "Newcastle upon Tyne (United Kingdom), London (United Kingdom), Connecticut, Texas", "NCTID": "NCT03907969", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132G", "Title": "Niraparib and Temozolomide in Treating Patients With Extensive_Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum_Based First_Line Chemotherapy", "StudyPhase": "PHASE 1/2", "Target": "PARP", "Locations": "California", "NCTID": "NCT03830918", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132G", "Title": "BGB_290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations", "StudyPhase": "PHASE 1/2", "Target": "PARP", "Locations": "California, Michigan, Missouri, Ohio, Pennsylvania, Massachusetts, Connecticut, Maryland, Virginia", "NCTID": "NCT03914742", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132G", "Title": "Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "California, Wisconsin, Missouri, Kansas", "NCTID": "NCT03212274", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132G", "Title": "PEN_866 in Patients With Advanced Solid Malignancies", "StudyPhase": "PHASE 1/2", "Target": "PARP, HSP90", "Locations": "Nevada, Colorado, Michigan, Oklahoma, Arkansas, Tennessee, Pennsylvania, Maryland, Virginia", "NCTID": "NCT03221400", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "20513808", "FullCitation": "Reitman ZJ, et al. J. Natl. Cancer Inst. (2010) pmid: 20513808", "Include": "true"}, {"number": "1", "ReferenceId": "21326614", "FullCitation": "Jin G, et al. PLoS ONE (2011) pmid: 21326614", "Include": "true"}, {"number": "2", "ReferenceId": "20142433", "FullCitation": "Gross S, et al. J. Exp. Med. (2010) pmid: 20142433", "Include": "true"}, {"number": "3", "ReferenceId": "20171147", "FullCitation": "Ward PS, et al. Cancer Cell (2010) pmid: 20171147", "Include": "true"}, {"number": "4", "ReferenceId": "22442146", "FullCitation": "Leonardi R, et al. J. Biol. Chem. (2012) pmid: 22442146", "Include": "true"}, {"number": "5", "ReferenceId": "19935646", "FullCitation": "Dang L, et al. Nature (2009) pmid: 19935646", "Include": "true"}, {"number": "6", "ReferenceId": "21996744", "FullCitation": "Ward PS, et al. Oncogene (2012) pmid: 21996744", "Include": "true"}, {"number": "7", "ReferenceId": "21130701", "FullCitation": "Figueroa ME, et al. Cancer Cell (2010) pmid: 21130701", "Include": "true"}, {"number": "8", "ReferenceId": "21251613", "FullCitation": "Xu W, et al. Cancer Cell (2011) pmid: 21251613", "Include": "true"}, {"number": "9", "ReferenceId": "22343889", "FullCitation": "Turcan S, et al. Nature (2012) pmid: 22343889", "Include": "true"}, {"number": "10", "ReferenceId": "22899282", "FullCitation": "Duncan CG, et al. Genome Res. (2012) pmid: 22899282", "Include": "true"}, {"number": "11", "ReferenceId": "24019001", "FullCitation": "Chaumeil MM, et al. Nat Commun (2013) pmid: 24019001", "Include": "true"}, {"number": "12", "ReferenceId": "23918605", "FullCitation": "Hartmann C, et al. Clin. Cancer Res. (2013) pmid: 23918605", "Include": "true"}, {"number": "13", "ReferenceId": "21885076", "FullCitation": "Rossetto M, et al. Rev. Neurol. (Paris) (2011) pmid: 21885076", "Include": "true"}, {"number": "14", "ReferenceId": "24129546", "FullCitation": "Shin JH, et al. J. Neurooncol. (2013) pmid: 24129546", "Include": "true"}, {"number": "15", "ReferenceId": "18772396", "FullCitation": "Parsons DW, et al. Science (2008) pmid: 18772396", "Include": "true"}, {"number": "16", "ReferenceId": "26061751", "FullCitation": "Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751", "Include": "true"}, {"number": "17", "ReferenceId": "24120142", "FullCitation": "Brennan CW, et al. Cell (2013) pmid: 24120142", "Include": "true"}, {"number": "18", "ReferenceId": "22904127", "FullCitation": "Thota B, et al. Am. J. Clin. Pathol. (2012) pmid: 22904127", "Include": "true"}, {"number": "19", "ReferenceId": "24140581", "FullCitation": "Killela PJ, et al. Oncotarget (2014) pmid: 24140581", "Include": "true"}, {"number": "20", "ReferenceId": "24559763", "FullCitation": "Haberler C, et al. Clin. Neuropathol. () pmid: 24559763", "Include": "true"}, {"number": "21", "ReferenceId": "19228619", "FullCitation": "Yan H, et al. N. Engl. J. Med. (2009) pmid: 19228619", "Include": "true"}, {"number": "22", "ReferenceId": "21088844", "FullCitation": "Hartmann C, et al. Acta Neuropathol. (2010) pmid: 21088844", "Include": "true"}, {"number": "23", "ReferenceId": "19765000", "FullCitation": "Sonoda Y, et al. Cancer Sci. (2009) pmid: 19765000", "Include": "true"}, {"number": "24", "ReferenceId": "22528790", "FullCitation": "Ahmadi R, et al. J. Neurooncol. (2012) pmid: 22528790", "Include": "true"}, {"number": "25", "ReferenceId": "23486687", "FullCitation": "Jiang H, et al. Neuro_oncology (2013) pmid: 23486687", "Include": "true"}, {"number": "26", "ReferenceId": "21971842", "FullCitation": "Shibahara I, et al. Int. J. Clin. Oncol. (2012) pmid: 21971842", "Include": "true"}, {"number": "27", "ReferenceId": "23015095", "FullCitation": "Juratli TA, et al. J. Neurooncol. (2012) pmid: 23015095", "Include": "true"}, {"number": "28", "ReferenceId": "19805672", "FullCitation": "Weller M, et al. J. Clin. Oncol. (2009) pmid: 19805672", "Include": "true"}, {"number": "29", "ReferenceId": "31028664", "FullCitation": "Fan B, et al. Invest New Drugs (2019) pmid: 31028664", "Include": "true"}, {"number": "30", "ReferenceId": "29719265", "FullCitation": "Philip B, et al. Cell Rep (2018) pmid: 29719265", "Include": "true"}, {"number": "31", "ReferenceId": "29339439", "FullCitation": "Molenaar RJ, et al. Clin. Cancer Res. (2018) pmid: 29339439", "Include": "true"}, {"number": "32", "ReferenceId": "28202508", "FullCitation": "Lu Y, et al. Cancer Res. (2017) pmid: 28202508", "Include": "true"}, {"number": "33", "ReferenceId": "28148839", "FullCitation": "Sulkowski PL, et al. Sci Transl Med (2017) pmid: 28148839", "Include": "true"}, {"number": "34", "ReferenceId": "30073642", "FullCitation": "Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642", "Include": "true"}, {"number": "35", "ReferenceId": "30220459", "FullCitation": "McBrayer SK, et al. Cell (2018) pmid: 30220459", "Include": "true"}, {"number": "36", "ReferenceId": "23916100", "FullCitation": "Clynes D, et al. Trends Biochem. Sci. (2013) pmid: 23916100", "Include": "true"}, {"number": "37", "ReferenceId": "23249563", "FullCitation": "Ratnakumar K, et al. Epigenetics (2013) pmid: 23249563", "Include": "true"}, {"number": "38", "ReferenceId": "22829774", "FullCitation": "Lovejoy CA, et al. PLoS Genet. (2012) pmid: 22829774", "Include": "true"}, {"number": "39", "ReferenceId": "23185534", "FullCitation": "Bower K, et al. PLoS ONE (2012) pmid: 23185534", "Include": "true"}, {"number": "40", "ReferenceId": "21719641", "FullCitation": "Heaphy CM, et al. Science (2011) pmid: 21719641", "Include": "true"}, {"number": "41", "ReferenceId": "25229770", "FullCitation": "Liau JY, et al. Am. J. Surg. Pathol. (2015) pmid: 25229770", "Include": "true"}, {"number": "42", "ReferenceId": "17296936", "FullCitation": "Nan X, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17296936", "Include": "true"}, {"number": "43", "ReferenceId": "14729260", "FullCitation": "Garrick D, et al. Gene (2004) pmid: 14729260", "Include": "true"}, {"number": "44", "ReferenceId": "21666677", "FullCitation": "Eustermann S, et al. Nat. Struct. Mol. Biol. (2011) pmid: 21666677", "Include": "true"}, {"number": "45", "ReferenceId": "25593184", "FullCitation": "Flynn RL, et al. Science (2015) pmid: 25593184", "Include": "true"}, {"number": "46", "ReferenceId": "7697714", "FullCitation": "Gibbons RJ, et al. Cell (1995) pmid: 7697714", "Include": "true"}, {"number": "47", "ReferenceId": "21252315", "FullCitation": "Jiao Y, et al. Science (2011) pmid: 21252315", "Include": "true"}, {"number": "48", "ReferenceId": "25608029", "FullCitation": "Fishbein L, et al. Nat Commun (2015) pmid: 25608029", "Include": "true"}, {"number": "49", "ReferenceId": "22416102", "FullCitation": "Cheung NK, et al. JAMA (2012) pmid: 22416102", "Include": "true"}, {"number": "50", "ReferenceId": "22367537", "FullCitation": "Molenaar JJ, et al. Nature (2012) pmid: 22367537", "Include": "true"}, {"number": "51", "ReferenceId": "23334666", "FullCitation": "Pugh TJ, et al. Nat. Genet. (2013) pmid: 23334666", "Include": "true"}, {"number": "52", "ReferenceId": "23702928", "FullCitation": "Cheung NK, et al. Nat. Rev. Cancer (2013) pmid: 23702928", "Include": "true"}, {"number": "53", "ReferenceId": "24148618", "FullCitation": "Marinoni I, et al. Gastroenterology (2014) pmid: 24148618", "Include": "true"}, {"number": "54", "ReferenceId": "24468746", "FullCitation": "Qadeer ZA, et al. J. Invest. Dermatol. (2014) pmid: 24468746", "Include": "true"}, {"number": "55", "ReferenceId": "26936505", "FullCitation": "Koschmann C, et al. Sci Transl Med (2016) pmid: 26936505", "Include": "true"}, {"number": "56", "ReferenceId": "23104868", "FullCitation": "Kannan K, et al. Oncotarget (2012) pmid: 23104868", "Include": "true"}, {"number": "57", "ReferenceId": "25427834", "FullCitation": "Reuss DE, et al. Acta Neuropathol. (2015) pmid: 25427834", "Include": "true"}, {"number": "58", "ReferenceId": "25143301", "FullCitation": "Sahm F, et al. Acta Neuropathol. (2014) pmid: 25143301", "Include": "true"}, {"number": "59", "ReferenceId": "31551363", "FullCitation": "Liang J, et al. Cancer Res (2020) pmid: 31551363", "Include": "true"}, {"number": "60", "ReferenceId": "34118569", "FullCitation": "Garbarino J, et al. Transl Oncol (2021) pmid: 34118569", "Include": "true"}, {"number": "61", "ReferenceId": "32846370", "FullCitation": "George SL, et al. EBioMedicine (2020) pmid: 32846370", "Include": "true"}, {"number": "62", "ReferenceId": "27157931", "FullCitation": "Louis DN, et al. Acta Neuropathol (2016) pmid: 27157931", "Include": "true"}, {"number": "63", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "64", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "65", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "66", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "67", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "68", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "69", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "70", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "71", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "72", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "73", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "74", "ReferenceId": "32322066", "FullCitation": "Touat M, et al. Nature (2020) pmid: 32322066", "Include": "true"}, {"number": "75", "ReferenceId": "30742119", "FullCitation": "Zhao J, et al. Nat. Med. (2019) pmid: 30742119", "Include": "true"}, {"number": "76", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "77", "ReferenceId": "27001570", "FullCitation": "Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570", "Include": "true"}, {"number": "78", "ReferenceId": "27683556", "FullCitation": "Johanns TM, et al. Cancer Discov (2016) pmid: 27683556", "Include": "true"}, {"number": "79", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "80", "ReferenceId": "32386112", "FullCitation": "Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112", "Include": "true"}, {"number": "81", "ReferenceId": "28912153", "FullCitation": "Johnson A, et al. Oncologist (2017) pmid: 28912153", "Include": "true"}, {"number": "82", "ReferenceId": "26699864", "FullCitation": "Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864", "Include": "true"}, {"number": "83", "ReferenceId": "32164609", "FullCitation": "Wang L, et al. BMC Cancer (2020) pmid: 32164609", "Include": "true"}, {"number": "84", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "85", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "86", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "87", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "88", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "89", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "90", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "91", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "92", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "93", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "94", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "95", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "96", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "97", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "98", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "99", "ReferenceId": "15914282", "FullCitation": "Uno M, et al. Cancer Lett. (2005) pmid: 15914282", "Include": "true"}, {"number": "100", "ReferenceId": "16711514", "FullCitation": "Uno M, et al. Int. J. Biol. Markers () pmid: 16711514", "Include": "true"}, {"number": "101", "ReferenceId": "22844452", "FullCitation": "Lass U, et al. PLoS ONE (2012) pmid: 22844452", "Include": "true"}, {"number": "102", "ReferenceId": "23009112", "FullCitation": "Faria MH, et al. APMIS (2012) pmid: 23009112", "Include": "true"}, {"number": "103", "ReferenceId": "24358143", "FullCitation": "Milinkovic V, et al. PLoS ONE (2013) pmid: 24358143", "Include": "true"}, {"number": "104", "ReferenceId": "23613880", "FullCitation": "Galatro TF, et al. PLoS ONE (2013) pmid: 23613880", "Include": "true"}, {"number": "105", "ReferenceId": "11939587", "FullCitation": "Schmidt MC, et al. J. Neuropathol. Exp. Neurol. (2002) pmid: 11939587", "Include": "true"}, {"number": "106", "ReferenceId": "11550308", "FullCitation": "Nozaki M, et al. Neuro_oncology (1999) pmid: 11550308", "Include": "true"}, {"number": "107", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "108", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "109", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "110", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "111", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "112", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "113", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "114", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "115", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "116", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "117", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "118", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "119", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "120", "ReferenceId": "22446188", "FullCitation": "Ma CX, et al. J. Clin. Invest. (2012) pmid: 22446188", "Include": "true"}, {"number": "121", "ReferenceId": "22965953", "FullCitation": "Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953", "Include": "true"}, {"number": "122", "ReferenceId": "26086967", "FullCitation": "Mohell N, et al. Cell Death Dis (2015) pmid: 26086967", "Include": "true"}, {"number": "123", "ReferenceId": "27179933", "FullCitation": "Fransson \u00c5, et al. J Ovarian Res (2016) pmid: 27179933", "Include": "true"}, {"number": "124", "ReferenceId": "26563132", "FullCitation": "Kwok M, et al. Blood (2016) pmid: 26563132", "Include": "true"}, {"number": "125", "ReferenceId": "30975914", "FullCitation": "Boudny M, et al. Haematologica (2019) pmid: 30975914", "Include": "true"}, {"number": "126", "ReferenceId": "28062704", "FullCitation": "Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704", "Include": "true"}, {"number": "127", "ReferenceId": "30127241", "FullCitation": "Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241", "Include": "true"}, {"number": "128", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "129", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "130", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "131", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "132", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "133", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "134", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "135", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "136", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "137", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "138", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "139", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "140", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "141", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "142", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "143", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "144", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "145", "ReferenceId": "8521522", "FullCitation": "Quelle DE, et al. Cell (1995) pmid: 8521522", "Include": "true"}, {"number": "146", "ReferenceId": "15878778", "FullCitation": "Mutat. Res. (2005) pmid: 15878778", "Include": "true"}, {"number": "147", "ReferenceId": "9484839", "FullCitation": "Gazzeri S, et al. Oncogene (1998) pmid: 9484839", "Include": "true"}, {"number": "148", "ReferenceId": "10498883", "FullCitation": "Oncogene (1999) pmid: 10498883", "Include": "true"}, {"number": "149", "ReferenceId": "16869746", "FullCitation": "Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746", "Include": "true"}, {"number": "150", "ReferenceId": "20549699", "FullCitation": "Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699", "Include": "true"}, {"number": "151", "ReferenceId": "10498896", "FullCitation": "Ruas M, et al. Oncogene (1999) pmid: 10498896", "Include": "true"}, {"number": "152", "ReferenceId": "17909018", "FullCitation": "Jones R, et al. Cancer Res. (2007) pmid: 17909018", "Include": "true"}, {"number": "153", "ReferenceId": "18843795", "FullCitation": "Haferkamp S, et al. Aging Cell (2008) pmid: 18843795", "Include": "true"}, {"number": "154", "ReferenceId": "12417717", "FullCitation": "Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717", "Include": "true"}, {"number": "155", "ReferenceId": "11518711", "FullCitation": "Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711", "Include": "true"}, {"number": "156", "ReferenceId": "9324288", "FullCitation": "Gombart AF, et al. Leukemia (1997) pmid: 9324288", "Include": "true"}, {"number": "157", "ReferenceId": "7780957", "FullCitation": "Yang R, et al. Cancer Res. (1995) pmid: 7780957", "Include": "true"}, {"number": "158", "ReferenceId": "8668202", "FullCitation": "Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202", "Include": "true"}, {"number": "159", "ReferenceId": "12606942", "FullCitation": "Greenblatt MS, et al. Oncogene (2003) pmid: 12606942", "Include": "true"}, {"number": "160", "ReferenceId": "10491434", "FullCitation": "Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434", "Include": "true"}, {"number": "161", "ReferenceId": "11255261", "FullCitation": "Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261", "Include": "true"}, {"number": "162", "ReferenceId": "9660926", "FullCitation": "Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926", "Include": "true"}, {"number": "163", "ReferenceId": "19260062", "FullCitation": "Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062", "Include": "true"}, {"number": "164", "ReferenceId": "10719365", "FullCitation": "Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365", "Include": "true"}, {"number": "165", "ReferenceId": "7777061", "FullCitation": "Koh J, et al. Nature (1995) pmid: 7777061", "Include": "true"}, {"number": "166", "ReferenceId": "20340136", "FullCitation": "McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136", "Include": "true"}, {"number": "167", "ReferenceId": "21462282", "FullCitation": "Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282", "Include": "true"}, {"number": "168", "ReferenceId": "905385", "FullCitation": "Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385", "Include": "true"}, {"number": "169", "ReferenceId": "24659262", "FullCitation": "Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262", "Include": "true"}, {"number": "170", "ReferenceId": "23190892", "FullCitation": "Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892", "Include": "true"}, {"number": "171", "ReferenceId": "10389768", "FullCitation": "Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768", "Include": "true"}, {"number": "172", "ReferenceId": "12853981", "FullCitation": "Rutter JL, et al. Oncogene (2003) pmid: 12853981", "Include": "true"}, {"number": "173", "ReferenceId": "18538737", "FullCitation": "Itahana K, et al. Cancer Cell (2008) pmid: 18538737", "Include": "true"}, {"number": "174", "ReferenceId": "10360174", "FullCitation": "Zhang Y, et al. Mol. Cell (1999) pmid: 10360174", "Include": "true"}, {"number": "175", "ReferenceId": "9529249", "FullCitation": "Zhang Y, et al. Cell (1998) pmid: 9529249", "Include": "true"}, {"number": "176", "ReferenceId": "25873077", "FullCitation": "Jafri M, et al. Cancer Discov (2015) pmid: 25873077", "Include": "true"}, {"number": "177", "ReferenceId": "26824661", "FullCitation": "Ceccarelli M, et al. Cell (2016) pmid: 26824661", "Include": "true"}, {"number": "178", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "179", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "180", "ReferenceId": "20129251", "FullCitation": "Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251", "Include": "true"}, {"number": "181", "ReferenceId": "23412337", "FullCitation": "Sottoriva A, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23412337", "Include": "true"}, {"number": "182", "ReferenceId": "16909113", "FullCitation": "Weber RG, et al. Oncogene (2007) pmid: 16909113", "Include": "true"}, {"number": "183", "ReferenceId": "11489817", "FullCitation": "Chakravarti A, et al. Clin. Cancer Res. (2001) pmid: 11489817", "Include": "true"}, {"number": "184", "ReferenceId": "21713760", "FullCitation": "Feng J, et al. Cancer (2012) pmid: 21713760", "Include": "true"}, {"number": "185", "ReferenceId": "21636552", "FullCitation": "Raabe EH, et al. Clin. Cancer Res. (2011) pmid: 21636552", "Include": "true"}, {"number": "186", "ReferenceId": "21843312", "FullCitation": "Liu W, et al. J. Exp. Clin. Cancer Res. (2011) pmid: 21843312", "Include": "true"}, {"number": "187", "ReferenceId": "21278246", "FullCitation": "Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246", "Include": "true"}, {"number": "188", "ReferenceId": "21871868", "FullCitation": "Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868", "Include": "true"}, {"number": "189", "ReferenceId": "22711607", "FullCitation": "Cen L, et al. Neuro_oncology (2012) pmid: 22711607", "Include": "true"}, {"number": "190", "ReferenceId": "23898052", "FullCitation": "Logan JE, et al. Anticancer Res. (2013) pmid: 23898052", "Include": "true"}, {"number": "191", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "192", "ReferenceId": "26715889", "FullCitation": "Gao J, et al. Curr Oncol (2015) pmid: 26715889", "Include": "true"}, {"number": "193", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "194", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "195", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "196", "ReferenceId": "24797823", "FullCitation": "Johnson DB, et al. Oncologist (2014) pmid: 24797823", "Include": "true"}, {"number": "197", "ReferenceId": "21460101", "FullCitation": "Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101", "Include": "true"}, {"number": "198", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "199", "ReferenceId": "22090362", "FullCitation": "Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362", "Include": "true"}, {"number": "200", "ReferenceId": "23569312", "FullCitation": "Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312", "Include": "true"}, {"number": "201", "ReferenceId": "7666917", "FullCitation": "Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917", "Include": "true"}, {"number": "202", "ReferenceId": "20687502", "FullCitation": "Adv Exp Med Biol (2010) pmid: 20687502", "Include": "true"}, {"number": "203", "ReferenceId": "9479083", "FullCitation": "Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083", "Include": "true"}, {"number": "204", "ReferenceId": "29543703", "FullCitation": "De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703", "Include": "true"}, {"number": "205", "ReferenceId": "26892650", "FullCitation": "Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650", "Include": "true"}, {"number": "206", "ReferenceId": "29405243", "FullCitation": "Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243", "Include": "true"}, {"number": "207", "ReferenceId": "8414022", "FullCitation": "Kaufman DK, et al. Neurology (1993) pmid: 8414022", "Include": "true"}, {"number": "208", "ReferenceId": "9622062", "FullCitation": "Bahuau M, et al. Cancer Res (1998) pmid: 9622062", "Include": "true"}, {"number": "209", "ReferenceId": "28699883", "FullCitation": "Chan AK, et al. Clin Neuropathol () pmid: 28699883", "Include": "true"}, {"number": "210", "ReferenceId": "27479139", "FullCitation": "Limm K, et al. PLoS ONE (2016) pmid: 27479139", "Include": "true"}, {"number": "211", "ReferenceId": "25387827", "FullCitation": "Tang B, et al. G3 (Bethesda) (2014) pmid: 25387827", "Include": "true"}, {"number": "212", "ReferenceId": "21356366", "FullCitation": "Kirovski G, et al. Am. J. Pathol. (2011) pmid: 21356366", "Include": "true"}, {"number": "213", "ReferenceId": "23265702", "FullCitation": "Limm K, et al. Eur. J. Cancer (2013) pmid: 23265702", "Include": "true"}, {"number": "214", "ReferenceId": "19097084", "FullCitation": "Stevens AP, et al. J. Cell. Biochem. (2009) pmid: 19097084", "Include": "true"}, {"number": "215", "ReferenceId": "27068473", "FullCitation": "Marjon K, et al. Cell Rep (2016) pmid: 27068473", "Include": "true"}, {"number": "216", "ReferenceId": "26912361", "FullCitation": "Mavrakis KJ, et al. Science (2016) pmid: 26912361", "Include": "true"}, {"number": "217", "ReferenceId": "26912360", "FullCitation": "Kryukov GV, et al. Science (2016) pmid: 26912360", "Include": "true"}, {"number": "218", "ReferenceId": "25087184", "FullCitation": "Limm K, et al. Eur. J. Cancer (2014) pmid: 25087184", "Include": "true"}, {"number": "219", "ReferenceId": "27929028", "FullCitation": "Wei R, et al. Sci Rep (2016) pmid: 27929028", "Include": "true"}, {"number": "220", "ReferenceId": "27556634", "FullCitation": "Zhao M, et al. BMC Genomics (2016) pmid: 27556634", "Include": "true"}, {"number": "221", "ReferenceId": "19887491", "FullCitation": "Huang HY, et al. Clin. Cancer Res. (2009) pmid: 19887491", "Include": "true"}, {"number": "222", "ReferenceId": "16778103", "FullCitation": "Marc\u00e9 S, et al. Clin. Cancer Res. (2006) pmid: 16778103", "Include": "true"}, {"number": "223", "ReferenceId": "20500769", "FullCitation": "Meyer S, et al. Exp. Dermatol. (2010) pmid: 20500769", "Include": "true"}, {"number": "224", "ReferenceId": "16618867", "FullCitation": "Wild PJ, et al. Arch Dermatol (2006) pmid: 16618867", "Include": "true"}, {"number": "225", "ReferenceId": "21412930", "FullCitation": "Kim J, et al. Genes Chromosomes Cancer (2011) pmid: 21412930", "Include": "true"}, {"number": "226", "ReferenceId": "25426549", "FullCitation": "Li CF, et al. Oncotarget (2014) pmid: 25426549", "Include": "true"}, {"number": "227", "ReferenceId": "26656376", "FullCitation": "He HL, et al. Medicine (Baltimore) (2015) pmid: 26656376", "Include": "true"}, {"number": "228", "ReferenceId": "24969958", "FullCitation": "Su CY, et al. Eur J Surg Oncol (2014) pmid: 24969958", "Include": "true"}, {"number": "229", "ReferenceId": "16818274", "FullCitation": "Mirebeau D, et al. Haematologica (2006) pmid: 16818274", "Include": "true"}, {"number": "230", "ReferenceId": "26088413", "FullCitation": "Becker AP, et al. Pathobiology (2015) pmid: 26088413", "Include": "true"}, {"number": "231", "ReferenceId": "27433286", "FullCitation": "Snezhkina AV, et al. Oxid Med Cell Longev (2016) pmid: 27433286", "Include": "true"}, {"number": "232", "ReferenceId": "26910893", "FullCitation": "Bistulfi G, et al. Oncotarget (2016) pmid: 26910893", "Include": "true"}, {"number": "233", "ReferenceId": "25407435", "FullCitation": "Antonopoulou K, et al. J. Invest. Dermatol. (2015) pmid: 25407435", "Include": "true"}, {"number": "234", "ReferenceId": "23816148", "FullCitation": "Maccioni L, et al. BMC Cancer (2013) pmid: 23816148", "Include": "true"}, {"number": "235", "ReferenceId": "26635288", "FullCitation": "Hyland PL, et al. Int J Epidemiol (2016) pmid: 26635288", "Include": "true"}, {"number": "236", "ReferenceId": "27960044", "FullCitation": "Lin X, et al. Cancer Sci. (2017) pmid: 27960044", "Include": "true"}, {"number": "237", "ReferenceId": "27994653", "FullCitation": "Zhi L, et al. J Cancer (2016) pmid: 27994653", "Include": "true"}, {"number": "238", "ReferenceId": "23361049", "FullCitation": "Gu F, et al. Br. J. Cancer (2013) pmid: 23361049", "Include": "true"}, {"number": "239", "ReferenceId": "2691236", "FullCitation": "Endoscopy (1989) pmid: 2691236", "Include": "true"}, {"number": "240", "ReferenceId": "31350521", "FullCitation": "Guccione E, et al. Nat. Rev. Mol. Cell Biol. (2019) pmid: 31350521", "Include": "true"}, {"number": "241", "ReferenceId": "31257072", "FullCitation": "Fedoriw A, et al. Cancer Cell (2019) pmid: 31257072", "Include": "true"}, {"number": "242", "ReferenceId": "31287990", "FullCitation": "Srour N, et al. Cancer Cell (2019) pmid: 31287990", "Include": "true"}, {"number": "243", "ReferenceId": "30916320", "FullCitation": "Gao G, et al. Nucleic Acids Res. (2019) pmid: 30916320", "Include": "true"}, {"number": "244", "ReferenceId": "31040154", "FullCitation": "Hansen LJ, et al. Cancer Res. (2019) pmid: 31040154", "Include": "true"}, {"number": "245", "ReferenceId": "29844120", "FullCitation": "Tang B, et al. Cancer Res. (2018) pmid: 29844120", "Include": "true"}, {"number": "246", "ReferenceId": "24928612", "FullCitation": "Munshi PN, et al. Oncologist (2014) pmid: 24928612", "Include": "true"}, {"number": "247", "ReferenceId": "26751376", "FullCitation": "de Oliveira SF, et al. PLoS ONE (2016) pmid: 26751376", "Include": "true"}, {"number": "248", "ReferenceId": "19478948", "FullCitation": "Lubin M, et al. PLoS ONE (2009) pmid: 19478948", "Include": "true"}, {"number": "249", "ReferenceId": "22825330", "FullCitation": "Tang B, et al. Cancer Biol. Ther. (2012) pmid: 22825330", "Include": "true"}, {"number": "250", "ReferenceId": "22252602", "FullCitation": "Collins CC, et al. Mol. Cancer Ther. (2012) pmid: 22252602", "Include": "true"}, {"number": "251", "ReferenceId": "21301207", "FullCitation": "Bertino JR, et al. Cancer Biol. Ther. (2011) pmid: 21301207", "Include": "true"}, {"number": "252", "ReferenceId": "21282358", "FullCitation": "Coulthard SA, et al. Mol. Cancer Ther. (2011) pmid: 21282358", "Include": "true"}, {"number": "253", "ReferenceId": "17912432", "FullCitation": "Miyazaki S, et al. Int. J. Oncol. (2007) pmid: 17912432", "Include": "true"}, {"number": "254", "ReferenceId": "11987241", "FullCitation": "Efferth T, et al. Blood Cells Mol. Dis. () pmid: 11987241", "Include": "true"}, {"number": "255", "ReferenceId": "18618081", "FullCitation": "Kindler HL, et al. Invest New Drugs (2009) pmid: 18618081", "Include": "true"}, {"number": "256", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "257", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "258", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "259", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "260", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "261", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "262", "ReferenceId": "11280776", "FullCitation": "Alonso M, et al. Cancer Res. (2001) pmid: 11280776", "Include": "true"}, {"number": "263", "ReferenceId": "24073290", "FullCitation": "Rodr\u00edguez_Hern\u00e1ndez I, et al. PLoS ONE (2013) pmid: 24073290", "Include": "true"}, {"number": "264", "ReferenceId": "18053027", "FullCitation": "Vladimirova V, et al. Neuropathol. Appl. Neurobiol. (2008) pmid: 18053027", "Include": "true"}, {"number": "265", "ReferenceId": "15331927", "FullCitation": "Martinez R, et al. Oncology (2004) pmid: 15331927", "Include": "true"}, {"number": "266", "ReferenceId": "15672285", "FullCitation": "Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285", "Include": "true"}, {"number": "267", "ReferenceId": "17498554", "FullCitation": "Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554", "Include": "true"}, {"number": "268", "ReferenceId": "12908754", "FullCitation": "Szybka M, et al. Clin. Neuropathol. () pmid: 12908754", "Include": "true"}, {"number": "269", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "270", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "271", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "272", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "273", "ReferenceId": "32530764", "FullCitation": "Mellinghoff IK, et al. J. Clin. Oncol. (2020) pmid: 32530764", "Include": "true"}, {"number": "274", "ReferenceId": "29860938", "FullCitation": "DiNardo CD, et al. N. Engl. J. Med. (2018) pmid: 29860938", "Include": "true"}, {"number": "275", "ReferenceId": "31300360", "FullCitation": "Lowery MA, et al. Lancet Gastroenterol Hepatol (2019) pmid: 31300360", "Include": "true"}, {"number": "276", "ReferenceId": "32416072", "FullCitation": "Abou_Alfa GK, et al. Lancet Oncol. (2020) pmid: 32416072", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2021_12_10 16:43:58", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "952x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "3 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "BRAIN", "disease_ontology": "Brain anaplastic astrocytoma", "flowcell_analysis": "2000019123", "gender": "male", "pathology_diagnosis": "Anaplastic astrocytoma", "percent_tumor_nuclei": "50", "pipeline_version": "v3.8.2", "purity_assessment": "75.4", "specimen": "ORD_1247965_01*US1204172.01", "study": "CLINICAL_F1CDx", "test_request": "ORD_1247965_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Brain", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX1", "mean_exon_depth": "937.91", "name": "SQ_US1204172.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.8102", "cds_effect": "2656_2659delGAGA", "depth": "511", "equivocal": "false", "functional_effect": "frameshift", "gene": "ATRX", "percent_reads": "81.02", "position": "chrX:76938088", "protein_effect": "E886fs*18", "status": "likely", "strand": "_", "transcript": "NM_000489", "dna_evidence": {"sample": "SQ_US1204172.01_1"}}, {"allele_fraction": "0.5076", "cds_effect": "3068G>A", "depth": "1308", "equivocal": "false", "functional_effect": "missense", "gene": "MAP3K1", "percent_reads": "50.76", "position": "chr5:56178095", "protein_effect": "R1023H", "status": "unknown", "strand": "+", "transcript": "NM_005921", "dna_evidence": {"sample": "SQ_US1204172.01_1"}}, {"allele_fraction": "0.4917", "cds_effect": "1772G>A", "depth": "905", "equivocal": "false", "functional_effect": "missense", "gene": "FANCA", "percent_reads": "49.17", "position": "chr16:89845355", "protein_effect": "R591Q", "status": "unknown", "strand": "_", "transcript": "NM_000135", "dna_evidence": {"sample": "SQ_US1204172.01_1"}}, {"allele_fraction": "0.3776", "cds_effect": "1636_1638delAAG", "depth": "580", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "SMARCA4", "percent_reads": "37.76", "position": "chr19:11106930", "protein_effect": "K546del", "status": "unknown", "strand": "+", "transcript": "NM_003072", "dna_evidence": {"sample": "SQ_US1204172.01_1"}}, {"allele_fraction": "0.1652", "cds_effect": "239C>T", "depth": "460", "equivocal": "false", "functional_effect": "missense", "gene": "PDCD1", "percent_reads": "16.52", "position": "chr2:242794970", "protein_effect": "A80V", "status": "unknown", "strand": "_", "transcript": "NM_005018", "dna_evidence": {"sample": "SQ_US1204172.01_1"}}, {"allele_fraction": "0.8394", "cds_effect": "817C>T", "depth": "1015", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "83.94", "position": "chr17:7577121", "protein_effect": "R273C", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1204172.01_1"}}, {"allele_fraction": "0.6063", "cds_effect": "158C>T", "depth": "127", "equivocal": "false", "functional_effect": "missense", "gene": "MLL", "percent_reads": "60.63", "position": "chr11:118307385", "protein_effect": "A53V", "status": "unknown", "strand": "+", "transcript": "NM_005933", "dna_evidence": {"sample": "SQ_US1204172.01_1"}}, {"allele_fraction": "0.4784", "cds_effect": "563G>A", "depth": "974", "equivocal": "false", "functional_effect": "missense", "gene": "IDH2", "percent_reads": "47.84", "position": "chr15:90631706", "protein_effect": "R188Q", "status": "unknown", "strand": "_", "transcript": "NM_002168", "dna_evidence": {"sample": "SQ_US1204172.01_1"}}, {"allele_fraction": "0.4056", "cds_effect": "394C>G", "depth": "715", "equivocal": "false", "functional_effect": "missense", "gene": "IDH1", "percent_reads": "40.56", "position": "chr2:209113113", "protein_effect": "R132G", "status": "known", "strand": "_", "transcript": "NM_005896", "dna_evidence": {"sample": "SQ_US1204172.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "0", "equivocal": "false", "gene": "MTAP", "number_of_exons": "8 of 8", "position": "chr9:21802699_21862058", "ratio": "0.29", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1204172.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2A", "number_of_exons": "5 of 5", "position": "chr9:21853212_21998002", "ratio": "0.29", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1204172.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2B", "number_of_exons": "5 of 5", "position": "chr9:21998748_22101832", "ratio": "0.3", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1204172.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "2.52", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}